Cargando…

What’s Next for the Standard Short-Course Regimen for Treatment of Multidrug-Resistant Tuberculosis

Detalles Bibliográficos
Autores principales:	Campbell, Jonathon R., Menzies, Dick
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The American Society of Tropical Medicine and Hygiene 2019
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6367614/ https://www.ncbi.nlm.nih.gov/pubmed/30652674 http://dx.doi.org/10.4269/ajtmh.18-0985

Ejemplares similares

Short-Course Regimen for Multidrug-Resistant Tuberculosis: A Decade of Evidence
por: Trébucq, Arnaud, et al.
Publicado: (2019)

Treatment outcome of standardized regimen in patients with multidrug resistant tuberculosis
por: Jain, Kalpesh, et al.
Publicado: (2014)

Improving Quality of Patient Data for Treatment of Multidrug- or Rifampin-Resistant Tuberculosis
por: Campbell, Jonathon R., et al.
Publicado: (2020)

Short-course treatment for multidrug-resistant tuberculosis: the STREAM trials
por: Moodley, Riya, et al.
Publicado: (2016)

Case Report: Dynamics of Acquired Fluoroquinolone Resistance under Standardized Short-Course Treatment of Multidrug-Resistant Tuberculosis
por: Ngabonziza, Jean Claude Semuto, et al.
Publicado: (2020)

Rapid diagnosis and shorter regimen for multidrug-resistant tuberculosis: A priority to improve treatment outcome
por: Prasad, Rajendra, et al.
Publicado: (2017)

Modelling the effect of short-course multidrug-resistant tuberculosis treatment in Karakalpakstan, Uzbekistan
por: Trauer, James M., et al.
Publicado: (2016)

Propensity Score-Based Approaches to Confounding by Indication in Individual Patient Data Meta-Analysis: Non-Standardized Treatment for Multidrug Resistant Tuberculosis
por: Fox, Gregory J., et al.
Publicado: (2016)

The impact of improved detection and treatment of isoniazid resistant tuberculosis on prevalence of multi-drug resistant tuberculosis: A modelling study
por: Romanowski, Kamila, et al.
Publicado: (2019)

The Short Report — What Next?
por: Clark, T. J. H.
Publicado: (1985)

Possible impact of the standardized Category IV regimen on multidrug-resistant tuberculosis patients in Mumbai
por: Udwadia, Zarir F, et al.
Publicado: (2016)

Predictors of Treatment Success for Multidrug Resistant Tuberculosis
por: Park, Sang Won
Publicado: (2016)

At Long Last: Short, All-Oral Regimens for Multidrug-Resistant Tuberculosis in the United States
por: Sinha, Pranay, et al.
Publicado: (2023)

Treatment outcomes 24 months after initiating short, all-oral bedaquiline-containing or injectable-containing rifampicin-resistant tuberculosis treatment regimens in South Africa: a retrospective cohort study
por: Ndjeka, Norbert, et al.
Publicado: (2022)

Course of Adverse Events during Short Treatment Regimen in Patients with Rifampicin-Resistant Tuberculosis in Burundi
por: Ciza, François, et al.
Publicado: (2020)

Identifying patients with multidrug-resistant tuberculosis who may benefit from shorter durations of treatment
por: Winters, Nicholas, et al.
Publicado: (2023)

Individualized Treatment Duration in Tuberculosis Treatment: Precision versus Simplicity
por: Adjobimey, Menonli, et al.
Publicado: (2021)

Treatments of Multidrug-Resistant Tuberculosis: Light at the End of the Tunnel
por: Lange, Christoph, et al.
Publicado: (2022)

Time to Culture Conversion and Regimen Composition in Multidrug-Resistant Tuberculosis Treatment
por: Tierney, Dylan B., et al.
Publicado: (2014)

Effectiveness and Safety of Short-term Regimen for Multidrug-resistant Tuberculosis Treatment: A Systematic Review of Cohort Studies
por: Mahardani, Putu Nandika, et al.
Publicado: (2022)

Treatment of drug-resistant tuberculosis
por: Pinto, Lancelot, et al.
Publicado: (2011)

Tuberculosis preventive treatment in people living with HIV—Is the glass half empty or half full?
por: Oxlade, Olivia, et al.
Publicado: (2021)

Concise Clinical Review of Hematologic Toxicity of Linezolid in Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: Role of Mitochondria
por: Oehadian, Amaylia, et al.
Publicado: (2022)

Fluoroquinolone resistance in multidrug-resistant tuberculosis patients
por: Lee, Hyun-Woo, et al.
Publicado: (2019)

Efficacy of directly observed treatment short-course intermittent regimen in spinal tuberculosis
por: Valsalan, Rejith, et al.
Publicado: (2012)

Comparative effectiveness of individualized longer and standardized shorter regimens in the treatment of multidrug resistant tuberculosis in a high burden country
por: Wahid, Abdul, et al.
Publicado: (2022)

Modeling treatment effect modification in multidrug-resistant tuberculosis in an individual patientdata meta-analysis
por: Liu, Yan, et al.
Publicado: (2021)

Trends in tuberculosis clinicians’ adoption of short-course regimens for latent tuberculosis infection
por: Feng, Pei-Jean I., et al.
Publicado: (2023)

Patient and health-care worker perspectives on the short-course regimen for treatment of drug-resistant tuberculosis in Karakalpakstan, Uzbekistan
por: Horter, Shona, et al.
Publicado: (2020)

Towards all-oral and shorter treatment regimens for drug-resistant tuberculosis
por: Weyer, Karin, et al.
Publicado: (2018)

Cost-Effectiveness of Adding Bedaquiline to Drug Regimens for the Treatment of Multidrug-Resistant Tuberculosis in the UK
por: Wolfson, Lara J., et al.
Publicado: (2015)

Value of pyrazinamide for composition of new treatment regimens for multidrug-resistant Mycobacterium tuberculosis in China
por: Xia, Hui, et al.
Publicado: (2020)

Comorbidities and treatment outcomes in multidrug resistant tuberculosis: a systematic review and meta-analysis
por: Samuels, Joel Philip, et al.
Publicado: (2018)

Implementation of the ‘Removed Injectable modified Short-course regimens for EXpert Multidrug Resistant Tuberculosis’ (RISE study) in Tanzania: a protocol for a mixed-methods process evaluation
por: Kalolo, Albino, et al.
Publicado: (2022)

Outcomes associated with standardized treatment regimens for extensively drug-resistant tuberculosis
por: Aggarwal, Anivita, et al.
Publicado: (2020)

Aggressive Regimens for Multidrug-Resistant Tuberculosis Decrease All-Cause Mortality
por: Mitnick, Carole D., et al.
Publicado: (2013)

Regimens to treat multidrug-resistant tuberculosis: past, present and future perspectives
por: Pontali, Emanuele, et al.
Publicado: (2019)

Cost-Effectiveness of All-Oral Regimens for the Treatment of Multidrug-Resistant Tuberculosis in Korea: Comparison With Conventional Injectable-Containing Regimens
por: Park, Hae-Young, et al.
Publicado: (2023)

Anemia with elevation of growth differentiation factor-15 level in linezolid treated multidrug-resistant tuberculosis: Case series of three patients
por: Oehadian, Amaylia, et al.
Publicado: (2022)

Absolute risk of tuberculosis among untreated populations with a positive tuberculin skin test or interferon-gamma release assay result: systematic review and meta-analysis
por: Campbell, Jonathon R, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_a694pml7cjftect06loupftsbp